Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
暂无分享,去创建一个
B. Zinman | C. Wanner | D. Fitchett | J. Lachin | E. Bluhmki | S. Inzucchi | U. Broedl | H. Woerle | O. Johansen | M. Mattheus | S. Hantel | T. Devins
[1] A. H. Dinsmore,et al. New England , 1894, Letters from America.
[2] Peter Libby,et al. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. , 2002, JAMA.
[3] F. Ovalle. 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes , 2009 .
[4] The Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies , 2010, The Lancet.
[5] Cardio-renal syndromes: report from the consensus conference of the Acute Dialysis Quality Initiative , 2009, European heart journal.
[6] Martin Schumacher,et al. Competing Risks and Multistate Models with R , 2011 .
[7] J.,et al. The New England Journal of Medicine , 2012 .
[8] R. Grempler,et al. Empagliflozin, a novel selective sodium glucose cotransporter‐2 (SGLT‐2) inhibitor: characterisation and comparison with other SGLT‐2 inhibitors , 2012, Diabetes, obesity & metabolism.
[9] G. Salles,et al. Prognostic Impact of Aortic Stiffness in High-Risk Type 2 Diabetic Patients , 2013, Diabetes Care.
[10] Deepak L. Bhatt,et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. , 2013, The New England journal of medicine.
[11] M. Roden,et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. , 2013, The lancet. Diabetes & endocrinology.
[12] H. Häring,et al. Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes , 2013, Diabetes Care.
[13] Craig Wilson,et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. , 2013, The New England journal of medicine.
[14] C. Kovacs,et al. Empagliflozin improves glycaemic and weight control as add‐on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24‐week, randomized, placebo‐controlled trial , 2014, Diabetes, obesity & metabolism.
[15] A. Mithal,et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. , 2014, The lancet. Diabetes & endocrinology.
[16] U. Broedl,et al. Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus , 2014, Circulation.
[17] U. Broedl,et al. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus , 2014, Cardiovascular Diabetology.
[18] H. Häring,et al. Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial , 2014, Diabetes Care.
[19] J. Rosenstock,et al. Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes , 2014, Diabetes Care.
[20] M. Ridderstråle,et al. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. , 2014, The lancet. Diabetes & endocrinology.
[21] I. Tikkanen,et al. Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension , 2014, Diabetes Care.
[22] G. Bakris,et al. Microalbuminuria as a Risk Predictor in Diabetes: The Continuing Saga , 2014, Diabetes Care.
[23] B. Zinman,et al. Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™) , 2014, Cardiovascular Diabetology.
[24] C. Cannon,et al. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes , 2015, Diabetes, obesity & metabolism.
[25] Deepak L. Bhatt,et al. Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials. , 2015, The lancet. Diabetes & endocrinology.
[26] B. Zinman,et al. SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials , 2015, Diabetes & vascular disease research.
[27] E. Wright,et al. Probing SGLT2 as a therapeutic target for diabetes: Basic physiology and consequences , 2015, Diabetes & vascular disease research.
[28] Daniel F. Freitag,et al. Association of Cardiometabolic Multimorbidity With Mortality. , 2015, JAMA.
[29] J. Rosenstock,et al. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78‐week randomized, double‐blind, placebo‐controlled trial , 2015, Diabetes, obesity & metabolism.
[30] M. Pencina,et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. , 2015, The New England journal of medicine.